Knight Therapeutics (TSE:GUD) Upgraded to “Moderate Buy” at Raymond James

Raymond James upgraded shares of Knight Therapeutics (TSE:GUD) to a moderate buy rating in a research note issued to investors on Friday,Zacks.com reports. Raymond James also issued estimates for Knight Therapeutics’ Q4 2024 earnings at $0.01 EPS, Q1 2025 earnings at $0.00 EPS and Q3 2025 earnings at $0.00 EPS.

GUD has been the subject of a number of other research reports. Stifel Canada raised shares of Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, August 12th. Stifel Nicolaus upgraded shares of Knight Therapeutics from a “hold” rating to a “buy” rating and increased their price target for the company from C$5.75 to C$6.75 in a research report on Tuesday, August 13th.

Knight Therapeutics Trading Up 3.5 %

GUD stock opened at C$5.37 on Friday. Knight Therapeutics has a fifty-two week low of C$5.07 and a fifty-two week high of C$6.23. The stock has a market capitalization of C$543.50 million, a price-to-earnings ratio of -26.85, a P/E/G ratio of -1,013.50 and a beta of 0.50. The company has a debt-to-equity ratio of 7.62, a current ratio of 3.41 and a quick ratio of 1.79. The business has a fifty day moving average price of C$5.70 and a 200 day moving average price of C$5.73.

Insider Buying and Selling at Knight Therapeutics

In other news, insider Sime Armoyan sold 300,000 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of C$6.13, for a total transaction of C$1,839,000.00. Also, Director Samira Sakhia purchased 20,000 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was bought at an average price of C$5.15 per share, with a total value of C$103,000.00. Insiders own 45.62% of the company’s stock.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.